Department of Oncology, Department of Orthopedics, Department of Otolaryngology; Caoxian People's Hospital, Heze, China.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9416-9422. doi: 10.26355/eurrev_202009_23026.
The purpose of this study was to investigate the potential effects of LIM and Src homology 3 (SH3) protein 2 (LASP2) on nasopharyngeal carcinoma (NPC) and the relevant mechanism.
The expression of LASP2 in NPC patients and non-cancer patients in the control group was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The patients were divided into LASP2 high-expression group (n=30) and low-expression group (n=30), according to the median expression level of LASP2. Then, the expression of LASP2 was detected in the chosen cell lines by qRT-PCR.
In qRT-PCR experiment, LASP2 was found up-expressed in NPC clinical samples and cell lines. Besides, LASP2 expression was associated with the clinical stage and distant metastasis of NPC. Next, the expression of LASP2 was downregulated by transfection of si-LASP using LipofectamineTM 3000 in 6-10B cells in vitro. The transfection effects of si-LASP2 were confirmed by qRT-PCR and Western-blot (WB) experiments. In supplementary experiments, decreased expression of LASP2 in cells could inhibit the cell biological functions, including invasion, migration, and epithelial-mesenchymal transition (EMT).
This research discovers the promotion effect of LASP2 on NPC, suggesting that LASP2 could be used as a potential therapeutic target for NPC.
本研究旨在探讨 LIM 和Src 同源结构域 3(SH3)蛋白 2(LASP2)对鼻咽癌(NPC)的潜在影响及其相关机制。
采用实时荧光定量聚合酶链反应(qRT-PCR)检测 NPC 患者和对照组非癌患者中 LASP2 的表达。根据 LASP2 的中位表达水平,将患者分为 LASP2 高表达组(n=30)和低表达组(n=30)。然后,通过 qRT-PCR 检测选定细胞系中 LASP2 的表达。
qRT-PCR 实验发现 LASP2 在 NPC 临床样本和细胞系中呈高表达。此外,LASP2 的表达与 NPC 的临床分期和远处转移有关。接下来,通过 LipofectamineTM 3000 转染 si-LASP 在体外下调 6-10B 细胞中的 LASP2 表达。通过 qRT-PCR 和 Western-blot(WB)实验证实了 si-LASP2 的转染效果。在补充实验中,细胞中 LASP2 的表达下调可抑制细胞的生物学功能,包括侵袭、迁移和上皮间质转化(EMT)。
本研究发现 LASP2 对 NPC 的促进作用,提示 LASP2 可作为 NPC 的潜在治疗靶点。